Schizophrenia linked to signalling problems in new brain study
Schizophrenia could be caused by faulty signalling in the brain, according to new research published today in the journal Molecular Psychiatry.
In the biggest study of its kind, scientists looking in detail at brain samples donated by people with the condition have identified 49 genes that work differently in the brains of schizophrenia patients compared to controls.
Many of these genes are involved in controlling cell-to-cell signaling in the brain. The study, which was carried out by researchers at Imperial College London and GlaxoSmithKline, supports the theory that abnormalities in the way in which cells "talk" to each other are involved in the disease.
Schizophrenia is thought to affect around one in 100 people. Symptoms vary but can include hallucinations, lack of motivation and impaired social functioning. The disorder has little physical effect on the brain and its causes are largely unknown.
Some scientists believe that schizophrenia could be caused by the brain producing too much dopamine, partly because drugs that block dopamine action provide an effective treatment for the condition. Another theory is that the coat surrounding nerve cells, which is made of myelin, is damaged in people with schizophrenia. However, the new study found that the genes for dopamine and for myelin were not acting any differently in schizophrenia patients compared with controls.
Professor Jackie de Belleroche, corresponding author of the paper from Imperial College London, said: "The first step towards better treatments for schizophrenia is to really understand what is going on, to find out what genes are involved and what they are doing. Our new study has narrowed the search for potential targets for treatment."
As well as pointing towards signaling as the cause of schizophrenia, the new findings could also lead to new ways of diagnosing the condition. At the moment, patients are diagnosed on the basis of their behaviour.
"Most patients are diagnosed as teenagers or in their early 20s, but if they could be diagnosed earlier, they could be treated more effectively and they could have a better quality of life. To have the possibility of transforming someone's life early on instead of having to take drugs indefinitely would be wonderful," added Professor de Belleroche.
The research was possible due to a successful collaboration between Imperial College and GlaxoSmithKline.